Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given a consensus rating of “Buy” by the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $45.63.
A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They issued an “overweight” rating for the company. BMO Capital Markets dropped their price objective on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, April 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price objective on shares of 4D Molecular Therapeutics in a report on Wednesday, June 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, June 7th.
Get Our Latest Stock Analysis on 4D Molecular Therapeutics
Insiders Place Their Bets
Institutional Trading of 4D Molecular Therapeutics
Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 415.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock valued at $16,539,000 after acquiring an additional 658,069 shares in the last quarter. Sectoral Asset Management Inc. bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at $2,887,000. Wellington Management Group LLP increased its stake in shares of 4D Molecular Therapeutics by 2.2% in the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock valued at $2,199,000 after acquiring an additional 3,638 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in 4D Molecular Therapeutics by 359.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after purchasing an additional 3,873 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in 4D Molecular Therapeutics by 3.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 268,638 shares of the company’s stock valued at $5,443,000 after purchasing an additional 10,130 shares during the period. Institutional investors own 99.27% of the company’s stock.
4D Molecular Therapeutics Trading Down 0.7 %
FDMT opened at $26.75 on Wednesday. The company’s 50 day moving average is $23.96 and its 200-day moving average is $25.08. 4D Molecular Therapeutics has a 1-year low of $9.44 and a 1-year high of $36.25. The company has a market cap of $1.38 billion, a P/E ratio of -10.96 and a beta of 2.84.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. On average, equities analysts forecast that 4D Molecular Therapeutics will post -2.98 EPS for the current year.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More
- Five stocks we like better than 4D Molecular Therapeutics
- Best Aerospace Stocks Investing
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- Using the MarketBeat Dividend Yield Calculator
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- Trading Halts Explained
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.